RECON: FDA halts Pepaxto trials; Pfizer nears $8B in vax sales for Q2

ReconReconAPIsBiologicsBiotechnologyCombination ProductsGlobalMedical DevicesOtherPharmaceuticalsRegulatory Intelligence/Policy